REG1 explained

REG1 is an anticoagulation system consisting of two drugs: pegnivacogin, a single-stranded 31-nucleotide aptamer that binds and inhibits Factor IXa, and anivamersen, a complementary sequence reversal 15-nucleotide control agent.[1] [2] REG1 mechanism of action It involves inhibition of Factor IXa.[3]

REG1 is being developed for use in patients undergoing percutaneous coronary intervention and the treatment of acute coronary syndrome.[4] REG1 is associated with severe allergic reactions.[5] In the phase 2b RADAR trial,[6] 12 allergic-like reactions occurred shortly after administration of pegnivacogin in three patients with histories of allergy.

In one clinical trial, it was found that there was no evidence that REG1 reduced ischaemic events or bleeding compared with bivalirudin.

Notes and References

  1. Lincoff . A. Michael . Mehran . Roxana . Povsic . Thomas J. . Zelenkofske . Steven L. . Huang . Zhen . Armstrong . Paul W. . Steg . P. Gabriel . Bode . Christoph . Cohen . Mauricio G. . Buller . Christopher . Laanmets . Peep . 2016-01-23 . Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial . The Lancet . English . 387 . 10016 . 349–356 . 10.1016/S0140-6736(15)00515-2 . 0140-6736 . 26547100. 10905525 .
  2. Sinha . Gunjan . 2013-12-01 . Regado's aptamer lines up against anticoagulants . Nature Biotechnology . en . 31 . 12 . 1060 . 10.1038/nbt1213-1060 . 476227 . 1546-1696.
  3. Becker RC, Chan MY . REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis . Curr. Opin. Mol. Ther. . 11 . 6 . 707–15 . December 2009 . 20072947 .
  4. Vavalle . John Paul . Cohen . Mauricio G . 2012 . The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome . Future Cardiology . 8 . 3 . 371–382 . 10.2217/fca.12.5 . 1479-6678 . 3739693 . 22420328.
  5. Lincoff . A. Michael . Mehran . Roxana . Povsic . Thomas J. . Zelenkofske . Steven L. . Huang . Zhen . Armstrong . Paul W. . Steg . P. Gabriel . Bode . Christoph . Cohen . Mauricio G. . Buller . Christopher . Laanmets . Peep . 2016-01-23 . Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial . Lancet . 387 . 10016 . 349–356 . 10.1016/S0140-6736(15)00515-2 . 1474-547X . 26547100. 10905525 .
  6. Povsic . Thomas J. . Vavalle . John P. . Aberle . Laura H. . Kasprzak . Jaroslaw D. . Cohen . Mauricio G. . Mehran . Roxana . Bode . Christoph . Buller . Christopher E. . Montalescot . Gilles . Cornel . Jan H. . Rynkiewicz . Andrzej . 2012-08-02 . A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial . European Heart Journal . 34 . 31 . 2481–2489 . 10.1093/eurheartj/ehs232 . 22859796 . 3895957 . 1522-9645.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "REG1".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.